Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 223.58 HKD for the Hong Kong stock and 28.57 USD for the US stock [4]. Core Insights - The company has shown steady revenue growth, with a projected increase in main revenue from 44.28 billion RMB in 2024 to 63.96 billion RMB in 2028, reflecting a compound annual growth rate (CAGR) of approximately 15.3% [2][9]. - The adjusted net profit for 2025 is expected to be 9.51 billion RMB, with a slight decline of 6.3% year-on-year, while the fourth quarter revenue for 2025 reached 14.51 billion RMB, up 12.3% year-on-year [9]. - The company is transitioning from a growth model driven solely by low prices to one that emphasizes quality and customer satisfaction, aiming to maintain its leading position in both business volume and profitability [9]. Financial Projections - Main revenue projections for the upcoming years are as follows: - 2024: 44,281 million RMB - 2025: 49,099 million RMB - 2026: 55,682 million RMB - 2027: 60,366 million RMB - 2028: 63,955 million RMB - The expected growth rates for these years are 15.3%, 10.9%, 13.4%, 8.4%, and 5.9% respectively [2][9]. - The projected earnings per share (EPS) are 10.88 RMB for 2024, increasing to 17.17 RMB by 2028 [2][9]. Cost Management and Efficiency - The company has successfully reduced its single-package transportation costs by 12.2% year-on-year, and sorting center operational costs by 3.7%, attributed to economies of scale and improved operational efficiencies [9]. - The ratio of selling, general, and administrative expenses to revenue has decreased from 6.1% to 5.4%, indicating ongoing cost control improvements [9]. Shareholder Returns - The company plans to enhance its shareholder return mechanism, targeting a total annual return of no less than 50% of the previous fiscal year's adjusted net profit starting in 2026 [9]. - A new share buyback plan of up to 1.5 billion USD is authorized for the next 24 months, reflecting management's confidence in long-term growth [9].

Investment Rating - The report maintains a "Buy" rating for the automotive industry, consistent with the previous rating [2] Core Insights - The automotive industry is expected to experience a stable price increase and volume growth in 2026, despite a decline in terminal sales in January and February due to consumer hesitation [15][16] - The passenger vehicle inventory has decreased for two consecutive months, and export growth has been impressive, with a 53.3% year-on-year increase in exports for the first two months of 2026 [15] - The penetration rate of new energy vehicles (NEVs) in the domestic market is under pressure, but exports have surged by 113.0% year-on-year [15] Summary by Sections 1. Passenger Vehicle Sales and Market Dynamics - In January and February 2026, the cumulative sales of passenger vehicles were 2.642 million units, down 14.7% year-on-year, indicating a projected annual decline of 5.3% [15] - The average selling price (ASP) of passenger vehicles increased by 8.8% year-on-year, marking five consecutive months of positive growth [15] - The inventory of passenger vehicles stood at 4.346 million units by the end of February 2026, with a dynamic inventory-to-sales ratio of 2.34 [15] 2. New Energy Vehicle Performance - The cumulative export of new energy vehicles reached 572,000 units in the first two months of 2026, reflecting a 113.0% year-on-year increase [15] - The penetration rates for pure electric and plug-in hybrid vehicles were 23.4% and 15.0%, respectively, with year-on-year declines of 9.2 percentage points and 3.0 percentage points [15] 3. Investment Recommendations - The report suggests focusing on various automotive companies based on their market positioning: - Right-side targets include Geely, BYD, Seres, Chery, Xpeng, and Leap Motor [15] - Left-side targets include Li Auto and Changan [15] - Companies at inflection points include Great Wall Motors and SAIC Motor, with a recommendation to pay attention to JAC Motors [15] - In the upstream and downstream supply chain, recommended right-side targets include Minth Group, Yinlun, and others, while left-side targets include Yongda Automotive and New Coordinates [15]

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of 3.90 CNY and a reasonable value estimated at 5.86 CNY [4]. Core Insights - Bohai Leasing has announced a share repurchase plan with a total fund range of 300-500 million CNY, aiming to buy back shares at a price not exceeding 7.36 CNY per share. This could involve repurchasing approximately 40.76 million to 67.93 million shares, representing 0.66% to 1.10% of the total share capital [1][2]. - The company is implementing a market value enhancement plan that includes focusing on its core aircraft leasing business, seeking quality acquisition targets for industry consolidation, and enhancing shareholder returns through improved operational performance and compliance with profit distribution systems [2]. Financial Forecast - Revenue is projected to grow from 33.68 billion CNY in 2023 to 49.12 billion CNY in 2025, with a growth rate of 5.5% in 2023 and 27.8% in 2025, followed by a decline in 2026 and 2027 [3]. - The net profit attributable to shareholders is expected to fluctuate significantly, with a forecast of 1.28 billion CNY in 2023, dropping to -315 million CNY in 2025, and then rebounding to 3.18 billion CNY in 2026 and 3.92 billion CNY in 2027 [3]. - Earnings per share (EPS) is anticipated to be 0.21 CNY in 2023, decreasing to -0.05 CNY in 2025, and then increasing to 0.51 CNY in 2026 and 0.63 CNY in 2027 [3].

Quantitative Models and Construction Methods - **Model Name**: Convolutional Neural Network (CNN) for Price-Volume Data **Model Construction Idea**: The model leverages convolutional neural networks to analyze standardized graphical representations of price-volume data, aiming to predict future price trends. The learned features are then mapped to specific industry theme indices[76][78] **Model Construction Process**: 1. Standardize price-volume data into graphical formats for each stock within a specific time window[76] 2. Train a convolutional neural network to extract features from these graphical representations[76] 3. Map the learned features to industry theme indices, such as dividend low-volatility, banking, and real estate indices[76][78] **Model Evaluation**: The model effectively identifies industry themes based on price-volume patterns, providing actionable insights for sector allocation[76][78] Model Backtesting Results - **CNN Model**: Latest theme configurations include the following indices: 1. CSI Dividend Low Volatility Index (h30269.CSI) 2. CSI Banking Index (399986.SZ) 3. CSI 800 Banking Index (h30022.CSI) 4. CSI Mainland Real Estate Theme Index (000948.CSI) 5. CSI 800 Real Estate Index (399965.SZ)[78] Quantitative Factors and Construction Methods - **Factor Name**: Macroeconomic Indicators **Factor Construction Idea**: Macroeconomic factors are used to assess their impact on asset returns by identifying trends and significant events in historical data[51][52] **Factor Construction Process**: 1. Track 25 domestic and international macroeconomic indicators, such as PMI, CPI, PPI, and M2 growth rates[52] 2. Define four types of macroeconomic events: short-term peaks/troughs, continuous up/down trends, historical highs/lows, and trend reversals[52] 3. Use historical moving averages to classify macroeconomic trends (e.g., 3-month, 12-month averages) and analyze their impact on asset returns over the next month[54] **Factor Evaluation**: The approach identifies effective macroeconomic events that significantly influence asset returns, providing a robust framework for market trend analysis[52][54] Factor Backtesting Results - **Macroeconomic Factors**: 1. PMI (3-month moving average): Positive outlook for equities[55] 2. Social Financing Stock YoY Growth (1-month moving average): Neutral outlook[55] 3. 10-Year Treasury Yield (12-month moving average): Neutral outlook[55] 4. Dollar Index (1-month moving average): Neutral outlook[55]

Investment Rating - The report assigns a "Buy" rating to the company with a current price of 29.82 HKD and a fair value of 39.24 HKD [4]. Core Insights - The company, Leshu, is a leading player in the sanitary products market in emerging markets, particularly in Africa, with significant market shares of 20% in baby diapers and 16% in sanitary napkins as of 2024 [8]. - The company has established a strong operational presence with eight factories and 18 sales branches across over 30 countries, indicating robust market penetration [8]. - The African sanitary products industry is expected to grow steadily, driven by population growth and economic development, with a compound annual growth rate (CAGR) of 6.8% from 2020 to 2024 [8]. - Leshu has built high barriers to entry through local production and channel management, positioning itself as a leader in the market [8]. - Future growth prospects include expanding into Latin America and diversifying product lines into daily consumer goods [8]. Financial Summary - Revenue projections for 2024 to 2028 show a steady increase from 454 million USD in 2024 to 875 million USD in 2028, with growth rates of 10.5%, 24.9%, 15.9%, 15.5%, and 15.2% respectively [2]. - Non-GAAP net profit is expected to rise from 98 million USD in 2024 to 186 million USD in 2028, reflecting growth rates of 24.4%, 15.3%, 14.2%, and 15.5% [2]. - The company's Non-GAAP EPS is projected to increase from 0.20 HKD in 2025 to 0.30 HKD in 2028, with a corresponding decrease in Non-GAAP PE from 20.9 to 12.7 [2]. - The expected Non-GAAP ROE is forecasted to remain strong, starting at 70.3% in 2024 and stabilizing around 20% by 2028 [2]. Market Position and Strategy - Leshu's strategy includes deepening market coverage through a robust distribution network, with plans to strengthen its presence in existing markets while exploring new regions [8]. - The company aims to leverage its local manufacturing capabilities to enhance product affordability and quality, thereby maintaining a competitive edge [8]. - The management team, with extensive experience in the fast-moving consumer goods sector, is focused on sustainable growth and operational efficiency [19].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 52.86 CNY per share based on a 25x PE valuation for the adjusted net profit in 2026 [6]. Core Insights - The company achieved a substantial profit growth of 24% when excluding stock-based compensation expenses, with a reported net profit of 5.04 billion CNY for the year, reflecting an 11.61% year-on-year increase [6]. - Revenue for the year reached 19.14 billion CNY, up 15.22% year-on-year, driven by a 19% increase in cash collections and a significant growth in AI-related services [6]. - The company is expanding its AI product matrix, which includes AI Mak, SourcingAI 2.0, and Mravin, enhancing its service offerings across various operational dimensions [6]. Financial Summary - Projected revenues for 2024 to 2028 are as follows: 1,669 million CNY (2024), 1,921 million CNY (2025), 2,258 million CNY (2026), 2,574 million CNY (2027), and 2,896 million CNY (2028), with growth rates of 9.3%, 15.1%, 17.5%, 14.0%, and 12.5% respectively [2]. - The expected net profit for the same period is projected to be 451 million CNY (2024), 504 million CNY (2025), 556 million CNY (2026), 715 million CNY (2027), and 831 million CNY (2028), with growth rates of 19.1%, 11.6%, 10.5%, 28.6%, and 16.2% respectively [2]. - The company’s EBITDA is forecasted to grow from 503 million CNY in 2024 to 908 million CNY in 2028, indicating a strong operational performance [2]. Market Performance - The company’s platform traffic increased by 33% year-on-year, with notable growth in emerging markets such as the Middle East and Latin America, both at 44% [6]. - The number of paid members for the China Manufacturing Network reached 29,793, with an annual increase of 2,378 members, while AI Mak's cash revenue surged by 88.49% year-on-year [6].

Investment Rating - The investment rating for the company is "Accumulate" [2] Core Views - The report highlights that the short-term impact of road network diversion is evident, but the ongoing renovation and expansion projects are expected to solidify long-term value [1] - The company has maintained a high dividend policy, proposing a cash dividend of 6.04 yuan per 10 shares for 2025, which reflects a 70% payout ratio of net profit attributable to shareholders [7] - Despite short-term revenue declines due to road network changes, the core asset renovation and expansion are progressing steadily, indicating strong future growth potential [7] Financial Performance Summary - In 2025, the company achieved operating revenue of 4.47 billion yuan, a year-on-year decrease of 2.19%, while net profit attributable to shareholders was 1.80 billion yuan, an increase of 15.31% [7] - The EBITDA for 2025 is projected at 3.69 billion yuan, with a slight decline in operating revenue expected in 2024 and 2025, followed by a gradual increase from 2026 onwards [6] - The company’s net profit for 2026 is estimated to be 1.56 billion yuan, with a projected EPS of 0.75 yuan per share [6][10] Revenue and Growth Forecast - The report forecasts a revenue growth rate of -6.3% for 2024, -2.2% for 2025, and a gradual recovery to 2.0% by 2028 [10] - The net profit growth rate is expected to be -4.4% in 2024, followed by a recovery to 3.3% by 2028 [10] Financial Ratios - The company’s P/E ratio is projected to be 19.7 in 2024, decreasing to 15.8 by 2028, indicating improving valuation over time [6] - The ROE is expected to decline slightly from 14.9% in 2024 to 12.8% in 2028, reflecting a stable but cautious growth outlook [6][10]

Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 12.20 and a fair value of HKD 18.74 [5]. Core Insights - The company is approaching commercialization of its first product, ABSK021, which has received approval from China's NMPA and is under review by the FDA for a specific indication [5]. - The company reported a revenue of RMB 612 million for 2025, reflecting a year-over-year growth of 21%, alongside a significant increase in adjusted profit [5]. - The company has a robust pipeline with multiple candidates in various stages of clinical development, which supports future growth potential [5]. Financial Forecast - The forecasted revenues for 2026, 2027, and 2028 are RMB 571 million, RMB 375 million, and RMB 726 million, respectively, with corresponding EPS of RMB 0.12, -0.29, and -0.03 [4][5]. - The company is expected to experience a dramatic revenue growth rate of 2,544.2% in 2024, followed by a more moderate growth of 21.5% in 2025, and a decline in subsequent years [4][8]. - The EBITDA for 2024 is projected at RMB 103 million, with a significant drop expected in 2027 to -RMB 199 million [4].

Core Viewpoints - The report emphasizes the continuous improvement of AI network density and scalability through new products in the optical fiber and cable industry, highlighting investment opportunities in this sector [1][6][13]. Market Review - The communication sector outperformed the CSI 300 index by 4.29 percentage points during the period from March 16 to March 20, 2026, with a sector increase of 2.10% compared to a decrease of 2.19% for the index [17]. - Over the past 30 days, the communication sector rose by 6.2%, significantly outperforming both the ChiNext and CSI 300 indices [18]. - Year-to-date, the communication sector has increased by 8.5%, again outperforming the broader market indices [18]. Industry Data Updates - As of the end of 2025, China had 4.838 million 5G base stations, marking a net increase of 588,000 from the previous year, with 5G stations accounting for 37.6% of all mobile phone base stations [30]. - In January 2026, the domestic smartphone shipment was 22.866 million units, a year-on-year decrease of 16.1%, with 5G smartphones making up 86.9% of total shipments [31]. - The number of mobile IoT terminal users reached 2.888 billion by the end of 2025, with a net increase of 232 million users [33]. Key Company Developments - Corning showcased multi-core fiber and MMC connectors at the OFC 2026, which are expected to enhance data center network density significantly. Their multi-core fiber solution can increase fiber capacity several times while reducing cable quality by up to 70% and installation time by up to 60% [6][14]. - Yangtze Optical Fibre and Cable demonstrated new AI-oriented optical fibers and ultra-high-speed interconnection solutions, including a hollow-core fiber with a length of 91.2 km and a loss of 0.04 dB/km, aimed at future AI computing centers [6][15]. - The report suggests focusing on the optical fiber and cable sector due to improving supply-demand dynamics and the introduction of high-value products, with a recommendation to pay attention to leading companies like Yangtze Optical Fibre, Hengtong Optic-Electric, Zhongtian Technology, and FiberHome [6][15].

Investment Rating - The report assigns a "Buy" rating with a target price of HKD 32.42, indicating a potential upside from the current price of HKD 21.98 [4]. Core Insights - The company's performance in 2025 met expectations, with total revenue of USD 548 million, a year-on-year decline of 13%. The oncology/immunology segment generated USD 286 million, down 21% year-on-year. The net profit for 2025 was USD 457 million, bolstered by a USD 416 million after-tax gain from the sale of non-core joint venture stakes [8][14]. - The FRUZAQLA product, marketed by Takeda, showed strong growth in overseas markets with sales of USD 366 million, a 25% increase year-on-year. However, domestic sales of the drug declined by 13% to USD 100.1 million [8][25]. - The ATTC platform has entered clinical trial phases, with multiple drug candidates progressing through various stages of development. The first candidate, HMPL-A251, began global Phase I/II trials in December 2025 for treating advanced or metastatic solid tumors [19][22]. Summary by Sections Performance Review - The report highlights that the 2025 performance was in line with expectations, with total revenue of USD 548 million and a net profit of USD 457 million. The decline in revenue was attributed to challenges in the oncology/immunology segment [8][14]. Clinical Pipeline and ATTC Platform - The clinical pipeline is rich with catalysts, including the ongoing trials for drugs like Sazetidine and Furuzanib, which are expected to expand market opportunities. The ATTC platform has successfully completed its multi-target clinical layout, with several candidates entering trials [15][19]. Earnings Forecast and Investment Recommendations - The report forecasts earnings per share (EPS) of USD 0.07, USD 0.08, and USD 0.13 for 2026, 2027, and 2028, respectively. The discounted cash flow (DCF) method suggests a fair value of HKD 32.42 per share, supporting the "Buy" rating [10][30].